Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America-Reference-Cited by-同舟云学术

Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

Published:2016-08-31 Issue:7 Volume:36 Page:700-712
ISSN:0271-9142
Container-title:Journal of Clinical Immunology
language:en
Short-container-title:J Clin Immunol

Author:

Suez Daniel,Stein Mark,Gupta Sudhir,Hussain Iftikhar,Melamed Isaac,Paris Kenneth,Darter Amy,Bourgeois Christelle,Fritsch Sandor,Leibl Heinz,McCoy Barbara,Gelmont David,Yel Leman

Funder

Baxalta

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s10875-016-0327-9.pdf

Reference38 articles.

1. Bousfiha A, Jeddane L, Al-Herz W, Ailal F, Casanova JL, Chatila T. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2015;35:727–38.

2. Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol. 2015;136:1186–1205.e78.

3. Modell V, Quinn J, Orange J, Notarangelo LD, Modell F. Primary immunodeficiencies worldwide: an updated overview from the Jeffrey Modell Centers Global Network. Immunol Res. 2016;64:736–53.